Article: Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings

Jan 15, 2025 Alzheimer's Disease Clinical Neurological Health

Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings

Objectives

To test the safety and efficacy of oral NR supplementation on cognition and Alzheimer's disease (AD) blood biomarkers in older adults with subjective cognitive decline and mild cognitive impairment (MCI).

Journal

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Key Outcomes

NR supplementation had no impact on cognition.
NR resulted in a 7% reduction in plasma pTau217 concentrations, a biomarker for AD, while placebo resulted in an 18% increase..

Duration

8 weeks

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 46 older adults with subjective cognitive decline and mild cognitive impairment (MCI)

See Published Study

Clinical

Nicotinamide Riboside Supplementation with Metabolic Activators Improves Cognitive Function in Parkinson’s Disease: Clinical Findings

Objectives To investigate whether supplementation of combined metabolic activators (CMA) consisting of NR, L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC), could be used to treat Parki...